Trial Profile
A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support prediction of the age appropriate dose of ticagrelor with similar levels of inhibition of platelet aggregation to 90 mg bd in adults
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2017
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Thromboembolism; Thrombosis
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 04 Feb 2013 New trial record